

Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases
Aug 14, 2024
Sarah Boyce, CEO of Avidity Biosciences, shares her inspiring journey from Liverpool to leading a company focusing on RNA medicines for rare muscle diseases. She discusses the innovative therapies being developed for conditions like myotonic dystrophy and Duchenne muscular dystrophy. The conversation dives into the challenges of transitioning to a CEO role and the significance of emotional intelligence in leadership. Boyce also highlights advancements in RNA therapeutics, including promising drug trials and the importance of community engagement in biotechnology.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8
Intro
00:00 • 2min
A Journey from Liverpool: Childhood and Early Influences
02:20 • 3min
From Challenges to Careers
05:33 • 7min
From Intern to Industry Leader
12:25 • 16min
Innovations in RNA Delivery
28:39 • 7min
Navigating Leadership Transitions in Biotechnology
35:56 • 2min
Transforming RNA Therapeutics
38:15 • 9min
Advancements in RNA Medicine for Muscle Diseases
47:09 • 21min